Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,059 stopped studies mapped to Carcinoma of Unknown Primary and descendants · 91% state a reason
Over the 2,059 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04543955 | Telotristat With Lutathera in Neuroendocrine Tumors | Phase 2 | terminated | Sep 10, 2020 | Lowell Anthony, MD | Sponsor cancelled research | Other (stated, no rule matched) |
| NCT01992861 | MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA… | — | terminated | Nov 25, 2013 | University of Washington | not stated | Not stated |
| NCT05153408 | (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | Phase 1 | terminated | Dec 10, 2021 | Blueprint Medicines Corporation | Lack of efficacy | Efficacy / futility |
| NCT03522584 | Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With… | Phase 1 / Phase 2 | terminated | May 11, 2018 | University of Washington | Terminated by the sponsor due to lack of efficacy in study treatment. | Efficacy / futility |
| NCT03824704 | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected… | Phase 2 | terminated | Jan 31, 2019 | pharmaand GmbH | Sponsor made a business decision to discontinue the study due to low accrual. | Enrollment / accrual |
| NCT05411679 | EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell… | Phase 2 | withdrawn | Jun 9, 2022 | Ellipses Pharma | Futility analysis decision to terminate EP0057 compound and all Ellipses sponsored studies… | Efficacy / futility |
| NCT03827850 | FGFR Inhibitor in FGFR Dysregulated Cancer(FIND) | Phase 2 | terminated | Feb 4, 2019 | Lung Cancer Group Cologne | Study-related difficulties faced with patient enrolment, no safety-related reasons | Safety / toxicity |
| NCT04348916 | Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With… | Phase 1 | terminated | Apr 16, 2020 | Oncorus, Inc. | Terminated due to Oncorus portfolio reprioritization | Sponsor / business decision |
| NCT05564338 | Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus… | Phase 3 | withdrawn | Oct 3, 2022 | BeiGene | Study has voluntarily discontinued due to a change in the company-level development strategy and is… | Safety / toxicity |
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch…(REFIT-MSS) | Phase 2 | withdrawn | Oct 17, 2022 | Translational Research in Oncology | Study never started/ will not proceed. | Other (stated, no rule matched) |
| NCT04305236 | Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast… | Phase 2 | terminated | Mar 12, 2020 | University of California, Irvine | Halted due to study funding | Funding |
| NCT04987996 | GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell… | Phase 2 | withdrawn | Aug 3, 2021 | Providence Health & Services | Study withdrawn due to lack of supply of one of the investigational agents. | Drug supply |
| NCT05886257 | Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T | Phase 2 | withdrawn | Jun 2, 2023 | Shi Ming | Protocol adjustment | Other (stated, no rule matched) |
| NCT03637803 | Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors | Phase 1 / Phase 2 | terminated | Aug 20, 2018 | 4D pharma plc | Sponsor insolvency | Other (stated, no rule matched) |
| NCT05375604 | A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma… | Phase 1 | terminated | May 16, 2022 | Codiak BioSciences | Company Bankruptcy | Sponsor / business decision |
| NCT03553212 | Twice High Dose External Beam Radiotherapy by Image-guided Tomotherapy for Organ-confined…(THRIP) | N/A | terminated | Jun 12, 2018 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | outdated, progress in clinical practice. | Other (stated, no rule matched) |
| NCT02344810 | C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating… | Phase 1 / Phase 2 | withdrawn | Jan 26, 2015 | Eastern Cooperative Oncology Group | The study did not open to accrual. No start date and no completion dates. | Enrollment / accrual |
| NCT00946712 | S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in… | Phase 3 | terminated | Jul 27, 2009 | SWOG Cancer Research Network | terminated at pre-planned futility analysis | Efficacy / futility |
| NCT00227617 | Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced… | Phase 2 / Phase 3 | terminated | Sep 28, 2005 | University of California, San Francisco | Low accrual | Enrollment / accrual |
| NCT03535675 | Muscadine Plus (MPX) In Men With Prostate Cancer | Phase 3 | terminated | May 24, 2018 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The study was terminated by DSMB due to futility. | Efficacy / futility |
| NCT04843319 | To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer(VERU-100) | Phase 1 / Phase 2 | terminated | Apr 13, 2021 | Veru Inc. | Study terminated as end points were not achieved at current dose level. | Other (stated, no rule matched) |
| NCT05743777 | PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head…(PROMOTE-HN) | Phase 2 | withdrawn | Feb 24, 2023 | Canadian Cancer Trials Group | Company withdrew financial support | Funding |
| NCT05774886 | Implantable Microdevice for TNBC - Pilot Study | Phase 1 | withdrawn | Mar 20, 2023 | Dana-Farber Cancer Institute | On hold | Other (stated, no rule matched) |
| NCT03515603 | Endocrine Outcome of Surgery for Pituitary Adenoma | N/A | terminated | May 3, 2018 | University of Ulm | Inadequate recruiting | Enrollment / accrual |
| NCT04603365 | Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell… | Phase 2 | withdrawn | Oct 26, 2020 | Jonsson Comprehensive Cancer Center | enrollment | Enrollment / accrual |
| NCT02345330 | Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck… | Phase 2 | terminated | Jan 26, 2015 | OncoSec Medical Incorporated | Due to company resource constraints | Sponsor / business decision |
| NCT05039736 | A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR… | Phase 2 | withdrawn | Sep 10, 2021 | M.D. Anderson Cancer Center | 0 participants accrued | Enrollment / accrual |
| NCT02036476 | Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma | Phase 2 | terminated | Jan 15, 2014 | Dana-Farber Cancer Institute | Lack of accrual. | Enrollment / accrual |
| NCT03823131 | Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and… | Phase 2 | terminated | Jan 30, 2019 | Chase Heaton, MD | Treatment Ineffective | Other (stated, no rule matched) |
| NCT03488472 | Radiosurgery Plus NovoTTF-200A for Metastatic Small Cell Lung Cancer to the Brain(RAD 1704) | N/A | terminated | Apr 5, 2018 | Drexell Hunter Boggs | This feasibility study only accrued one patient since site activation. We believe that the primary… | Enrollment / accrual |
| NCT04335006 | A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus… | Phase 3 | terminated | Apr 6, 2020 | Jiangsu HengRui Medicine Co., Ltd. | Sponsor R \& D Strategy Adjustment | Sponsor / business decision |
| NCT05368506 | ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian… | Early Phase 1 | withdrawn | May 10, 2022 | OHSU Knight Cancer Institute | PI discretion | Other (stated, no rule matched) |
| NCT02174575 | Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery | Phase 4 | withdrawn | Jun 25, 2014 | Tokyo Medical and Dental University | I retired my post before enrollment | Enrollment / accrual |
| NCT03662841 | Ablative Chemoembolization for Unresectable and Large Hepatocellular Carcinoma | N/A | terminated | Sep 10, 2018 | Chinese University of Hong Kong | poor patient accrual | Enrollment / accrual |
| NCT03808766 | A Study on the Angioarchitecture of Hepatocellular Carcinoma | N/A | terminated | Jan 18, 2019 | Chinese University of Hong Kong | Poor patient accrual | Enrollment / accrual |
| NCT05249569 | Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma | Phase 2 | terminated | Feb 21, 2022 | University of Texas Southwestern Medical Center | Sponsor pulled support for one of the study drugs. | Other (stated, no rule matched) |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | Phase 1 | terminated | Mar 3, 2015 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT03802058 | Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer | Phase 2 | terminated | Jan 14, 2019 | Wuhan University | The study was halted because enrollment was too slow | Enrollment / accrual |
| NCT03002103 | A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel… | Phase 3 | suspended | Dec 23, 2016 | SynCore Biotechnology Co., Ltd. | study design reconsideration | Other (stated, no rule matched) |
| NCT04590781 | Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or… | Phase 1 / Phase 2 | terminated | Oct 19, 2020 | Xencor, Inc. | The study has been terminated early by the sponsor due to business decision. | Sponsor / business decision |
| NCT04650451 | Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects… | Phase 1 | suspended | Dec 2, 2020 | Bellicum Pharmaceuticals | Due to a Dose Limiting Toxicity in another sister trial with same technology. | Safety / toxicity |
| NCT05220748 | RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients… | Phase 1 | withdrawn | Feb 2, 2022 | Rakuten Medical, Inc. | Decision was made due to a strategic re-evaluation of pipelines; no patients were enrolled. | Enrollment / accrual |
| NCT04085991 | Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate…(CROSSBOW) | Phase 2 | terminated | Sep 11, 2019 | Sir Mortimer B. Davis - Jewish General Hospital | Drug no longer available | Other (stated, no rule matched) |
| NCT04852367 | PanDox: Targeted Doxorubicin in Pancreatic Tumours(PanDox) | Phase 1 | withdrawn | Apr 21, 2021 | University of Oxford | Lack of recruitment | Enrollment / accrual |
| NCT03729245 | A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared… | Phase 3 | terminated | Nov 2, 2018 | Nektar Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT04110249 | Photoacoustic Imaging for Measuring Tumors and Normal Tissue in Patients With Head and… | N/A | terminated | Oct 1, 2019 | Roswell Park Cancer Institute | equipment issues | Other (stated, no rule matched) |
| NCT04150874 | Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow… | Early Phase 1 | terminated | Nov 5, 2019 | H. Lee Moffitt Cancer Center and Research Institute | Slow Accrual | Enrollment / accrual |
| NCT04489940 | Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative… | Phase 2 | terminated | Jul 28, 2020 | EMD Serono Research & Development Institute, Inc. | The study was prematurely discontinued by the sponsor due to probability of success which was too… | Enrollment / accrual |
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory… | Phase 1 | terminated | Sep 7, 2016 | Pfizer | not stated | Not stated |
| NCT04442581 | Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer | Phase 2 | terminated | Jun 22, 2020 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Jun 27, 2023source: clinicaltrials